Infliximab-induced bullous pemphigoid and anti-desmoglein 3 and anti-BP180 autoantibodies in a patient with ulcerative colitis
- 1 January 2019
- journal article
- letter
- Published by JLE in European Journal Of Dermatology
- Vol. 29 (1) , 88-90
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Etanercept-induced generalization of chronic, localized, anogenital bullous pemphigoid in a psoriatic patientJAAD Case Reports, 2016
- Infliximab-induced autoantibodies: a multicenter studyClinical Rheumatology, 2015
- Bullous pemphigoid occurring under anti-tumor necrosis factor-α therapyInternational Journal of Colorectal Disease, 2014
- Epidermolysis bullosa acquisita and inflammatory bowel disease: a review of the literatureClinical and Experimental Dermatology, 2013
- Biologics-induced autoimmune diseasesCurrent Opinion in Rheumatology, 2013
- Drug-induced bullous pemphigoid: cases triggered by intravenous iodine and etanerceptClinical and Experimental Dermatology, 2011
- Contrasting effects of TNF and anti‐TNF on the activation of effector T cells and regulatory T cells in autoimmunityFEBS Letters, 2011
- Autoimmune Bullous Skin Diseases Occurring under Anti-Tumor Necrosis Factor Therapy: Two Case ReportsDermatology, 2010
- Development of bullous pemphigoid during treatment of psoriasis with adalimumabClinical and Experimental Dermatology, 2009
- Bullous Pemphigoid during Long-Term TNF-α Blocker TherapyDermatology, 2009